Kinomica
Phosphoproteomic diagnostic platform for precision oncology therapy selection.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Early VC | ||
| Total Funding | 000k | ||
| GBP | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 165 % | (59 %) | - | 317 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (179 %) | (195 %) | (851 %) | (780 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (196 %) | (205 %) | (823 %) | (836 %) | (211 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 147 % | - | - | - | - |
Source: Company filings or news article
Related Content
Kinomica is a biotechnology company that develops phosphoproteomic diagnostic platforms designed to improve tailored treatment decisions for anticancer drug therapies. The company was founded in 2016 as a spin-out from the Barts Cancer Institute at Queen Mary University of London by Professor Pedro Cutillas, Professor John Gribben, and Dr. David Britton. The founding was the culmination of over 15 years of academic research by Professor Cutillas and his team into cell signaling and proteomics.
The company's core offering is the KScan® platform, which utilizes advanced bioinformatics and phosphoproteomics to directly measure the activity of multiple endogenous kinases and provide comprehensive cell signal network coverage. This enables a deeper understanding of disease mechanisms, improved drug targeting, and biomarker identification. Unlike genomic approaches, KScan® analyzes the phosphorylation signature of proteins, providing a direct snapshot of protein and cell-signaling activity, which may predict drug response more accurately. The platform is designed to be used at every stage of the drug development process, from identifying novel drug targets to investigating drug resistance and stratifying patients for clinical trials.
Kinomica operates in the biotechnology, life sciences, and digital health markets, with a specific focus on oncology. Its primary clients are pharmaceutical companies, and it has secured commercial agreements with several major players, including AstraZeneca. The business model involves providing its KScan® platform as a service to pharma partners to support the development of precision medicines and companion diagnostics. The company has raised a total of $13.1M in funding from investors including BGF, Longwall Ventures, Mercia Ventures, and BioCity.
Keywords: phosphoproteomics, precision oncology, diagnostic platform, biomarker discovery, cancer treatment, cell signaling, kinase inhibitors, companion diagnostics, drug development, bioinformatics, patient stratification, proteomics, targeted therapy, anti-cancer drugs, molecular diagnostics, drug resistance, life sciences, biotechnology, KScan, acute myeloid leukaemia